Shanghai Zaixin Pharmaceutical Technology

Shanghai Zaixin Pharmaceutical Technology is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases, particularly heart failure and cardiomyopathies. Founded in 2017 by Dr. Jidong Wang, a veteran in cardiac drug discovery, the company leverages deep expertise in cardiac mechanics to develop small molecules and gene therapies. Its lead candidate, ZX-001, is a novel cardiac myosin activator currently in Phase 2 clinical trials for heart failure with reduced ejection fraction (HFrEF). Zaixin's pipeline also includes ZX-002 for hypertrophic cardiomyopathy and early-stage gene therapy programs targeting calcium handling. The company is backed by leading investors including Sequoia China and Matrix Partners China.